Trulieve Cannabis
Trulieve Cannabis' revenue fell 0.5% to $1.2 billion in fiscal 2025. Its operating margin was 12.2%, up from 8.2% a year earlier. Free cash flow was $229 million, up 53.6%. The diluted share count rose 0.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
From fiscal 2019 to 2021, earnings per share fell 32.4% a year and net income 42.8% a year, as new shares raised the share count by 27% and diluted each share's earnings. Trulieve Cannabis then lost money in fiscal 2022, 2023, 2024 and 2025.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 227 | 207 | 201 | 299 | 256 |
| Debt incl. finance leases | 534 | 626 | 432 | 442 | 212 |
| Net debt (negative means net cash) | 308 | 419 | 231 | 143 | −44 |
| Net debt to EBITDA | 1.2x | 2.5x | — | 0.7x | −0.2x |
| Debt to equity | 0.2x | 0.3x | 0.3x | 0.3x | 0.2x |
| Interest coverage | 7.0x | 0.7x | −2.7x | 1.6x | 2.3x |
| Current ratio | 3.1x | 2.8x | 4.2x | 4.4x | 4.4x |
| Quick ratio | 1.9x | 1.5x | 2.3x | 2.7x | 2.5x |
Cash flow
Projections
Project Trulieve Cannabis' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Trulieve Cannabis shares on the open market, and 1 insider sold $14.7 million, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jun 26, 2026 | Kim A. RiversChairman and CEO, Director, 10% owner | Sold plan | 136,811 | $8.76 | $1.2 million | Form 4 |
| Jun 25, 2026 | Kim A. RiversChairman and CEO, Director, 10% owner | Sold plan | 300,000 | $8.17 | $2.5 million | Form 4 |
| Jun 24, 2026 | Kim A. RiversChairman and CEO, Director, 10% owner | Sold plan | 400,000 | $8.17 | $3.3 million | Form 4 |
| Jun 23, 2026 | Kim A. RiversChairman and CEO, Director, 10% owner | Sold plan | 380,000 | $8.47 | $3.2 million | Form 4 |
| Jun 22, 2026 | Kim A. RiversChairman and CEO, Director, 10% owner | Sold plan | 204,815 | $9.35 | $1.9 million | Form 4 |
| Jun 18, 2026 | Kim A. RiversChairman and CEO, Director, 10% owner | Sold plan | 139,846 | $9.46 | $1.3 million | Form 4 |
| Jun 17, 2026 | Kim A. RiversChairman and CEO, Director, 10% owner | Sold plan | 137,535 | $9.36 | $1.3 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 6 of 9 | 5 of 9 |
| Rule of 40 | 7.0% | 17.6% | 18.9% |
| Altman Z'' | 0.68 | 1.20 | 1.09 |
| Accruals ratio | −24.0% | −15.4% | −14.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 4 of 9 | 6 of 9 | 5 of 9 |
Compare
Put Trulieve Cannabis side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Trulieve Cannabis | FY25 | −0.5% | 12.2% | 19.4% | 5.8% | −0.2x | 5 | |
| SNDL | FY25 | 2.8% | −0.7% | 6.1% | — | — | — | Compare |
| Nu Skin | FY25 | −14.3% | 4.4% | 3.1% | 6.5% | −0.1x | 7 | Compare |
| USANA Health Sciences | FY25 | 8.3% | 4.0% | 0.9% | — | — | — | Compare |
| e.l.f. Beauty | FY26 | 24.6% | 4.5% | 11.6% | 3.8% | 3.6x | 4 | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 253 | 522 | 932 | 1,218 | 1,129 | 1,186 | 1,181 |
| Revenue growth | — | 106.3% | 78.7% | 30.7% | −7.3% | 5.1% | −0.5% |
| Gross profit | 192 | 386 | 567 | 689 | 589 | 716 | 711 |
| Research and development | — | — | — | — | — | — | — |
| Operating income | 113 | 218 | 204 | 50 | −222 | 98 | 144 |
| Net income | 53 | 63 | 17 | −253 | −533 | −161 | −122 |
| Diluted EPS (US$) | 0.46 | 0.53 | 0.21 | −0.95 | −2.28 | −0.79 | −0.58 |
| Diluted shares (millions) | 115 | 118 | 147 | 188 | 189 | 190 | 191 |
| Cash flow | |||||||
| Cash from operations | 19 | 100 | 13 | 23 | 202 | 272 | 273 |
| Capital expenditure | 72 | 100 | 276 | 165 | 40 | 123 | 44 |
| Free cash flow | −53 | −0 | −263 | −142 | 162 | 149 | 229 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 20 | 28 | 44 | 28 | 0 | 0 | 0 |
| Stock-based compensation | — | 3 | 9 | 18 | 11 | 20 | 20 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 92 | 147 | 227 | 207 | 201 | 299 | 256 |
| Debt incl. finance leases | — | 45 | 534 | 626 | 432 | 442 | 212 |
| Total assets | — | 810 | 3,411 | 3,400 | 2,729 | 2,870 | 2,696 |
| Total liabilities | — | 362 | 1,264 | 1,473 | 1,320 | 1,621 | 1,553 |
| Shareholders' equity | 133 | 448 | 2,147 | 1,928 | 1,409 | 1,249 | 1,143 |
| Margins and ratios | |||||||
| Gross margin | 75.9% | 74.1% | 60.8% | 56.6% | 52.1% | 60.3% | 60.2% |
| Operating margin | 44.8% | 41.9% | 21.9% | 4.1% | −19.6% | 8.2% | 12.2% |
| Net margin | 21.0% | 12.1% | 1.9% | −20.8% | −47.2% | −13.5% | −10.3% |
| Free cash flow margin | −20.9% | −0.1% | −28.2% | −11.6% | 14.3% | 12.6% | 19.4% |
| Rule of 40 (growth + FCF margin) | — | 106.2% | 50.5% | 19.1% | 7.0% | 17.6% | 18.9% |
| Return on capital | — | — | 7.3% | 1.6% | −8.8% | 3.2% | 5.8% |
| Return on equity | — | — | 1.3% | −12.4% | −32.0% | −12.1% | −10.2% |
| Return on assets | — | — | 0.8% | −7.4% | −17.4% | −5.7% | −4.4% |
| Net debt to EBITDA | — | −0.4x | 1.2x | 2.5x | — | 0.7x | −0.2x |